Payment overview · 2025
General Payments
$1,664.15
49 reported records · 11 companies
Healthcare provider profile · identity verified
Ajith K Karayil, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRONX, NY · NPI 1104011618
Verified facts
What the public records show
CMS Open Payments records show Ajith K Karayil, MD received $1,664.15 in general payments during 2025 across 49 reported records.
Novo Nordisk Inc accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $506.52 | 30.4% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $379.27 | 22.8% | 13 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $168.93 | 10.2% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.00 | 7.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $95.87 | 5.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.59 | 3.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.96 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.57 | 1.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.44 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,664.15 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $506.52 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $256.52 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $247.51 | 7 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $168.93 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $95.87 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.87 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $64.59 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.89 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 150 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 296 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
150 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
296 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 928 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 774 | 191 |
| Simvastatin | Simvastatin | 773 | 208 |
| Atorvastatin Calcium | Atorvastatin Calcium | 665 | 172 |
| Metformin Hcl | Metformin Hcl | 621 | 158 |
| Omeprazole | Omeprazole | 610 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 579 | 136 |
| Diclofenac Sodium | Diclofenac Sodium | 555 | 165 |
| Fluticasone Propionate | Fluticasone Propionate | 460 | 136 |
| Famotidine | Famotidine | 444 | 123 |
| Losartan Potassium | Losartan Potassium | 432 | 116 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 427 | 114 |
| Glipizide Er | Glipizide | 375 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 347 | 96 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 325 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 88 |
| Jardiance | Empagliflozin | 296 | 57 |
| Gabapentin | Gabapentin | 292 | 60 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 282 | 87 |
| Lisinopril | Lisinopril | 271 | 66 |
| Meclizine Hcl | Meclizine Hcl | 271 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 60 |
| Januvia | Sitagliptin Phosphate | 209 | 33 |
| Tradjenta | Linagliptin | 186 | 33 |
| Trazodone Hcl | Trazodone Hcl | 180 | 30 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 170 | 57 |
| Montelukast Sodium | Montelukast Sodium | 164 | 32 |
| Alendronate Sodium | Alendronate Sodium | 154 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 37 |
| Ozempic | Semaglutide | 152 | 22 |
| Eliquis | Apixaban | 151 | 28 |
| Farxiga | Dapagliflozin Propanediol | 150 | 27 |
| Furosemide | Furosemide | 149 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 41 |
| Donepezil Hcl | Donepezil Hcl | 137 | 40 |
| Nifedipine Er | Nifedipine | 137 | 29 |
| Entresto | Sacubitril/Valsartan | 129 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 127 | 26 |
| Ammonium Lactate | Ammonium Lactate | 126 | 29 |
| Novolog Flexpen | Insulin Aspart | 122 | 23 |
| Betamethasone Valerate | Betamethasone Valerate | 105 | 35 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 104 | 20 |
| Naproxen | Naproxen | 101 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 18 |
| Prednisone | Prednisone | 93 | 41 |
| Single Use Swab | Alcohol Antiseptic Pads | 88 | 31 |
| Ezetimibe | Ezetimibe | 86 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 84 | 21 |
| Amoxicillin | Amoxicillin | 81 | 63 |
| Buspirone Hcl | Buspirone Hcl | 80 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 79 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 15 |
| Carvedilol | Carvedilol | 72 | 18 |
| Meloxicam | Meloxicam | 71 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 54 |
| Lactulose | Lactulose | 68 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 25 |
| Azithromycin | Azithromycin | 63 | 46 |
| Fenofibrate | Fenofibrate | 62 | 13 |
| Ibuprofen | Ibuprofen | 62 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 17 |
| Sertraline Hcl | Sertraline Hcl | 56 | 13 |
| Enulose | Lactulose | 55 | 21 |
| Tramadol Hcl | Tramadol Hcl | 54 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 19 |
| Glipizide Xl | Glipizide | 50 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Spironolactone | Spironolactone | 48 | suppressed |
| Allopurinol | Allopurinol | 47 | 11 |
| Enalapril Maleate | Enalapril Maleate | 47 | 11 |
| Procto-Med Hc | Hydrocortisone | 47 | 14 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 12 |
| Finasteride | Finasteride | 45 | 15 |
| Atenolol | Atenolol | 44 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 11 |
| Linzess | Linaclotide | 42 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 41 | suppressed |
| Folic Acid | Folic Acid | 40 | 12 |
| Telmisartan | Telmisartan | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 30 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 14 |
| Glipizide | Glipizide | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | 11 |
| Torsemide | Torsemide | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 32 | 16 |
| Halobetasol Propionate | Halobetasol Propionate | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Alcohol Wipes | Alcohol Antiseptic Pads | 30 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,664.15 · 49 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FANAPT, FARXIGA, FUROSCIX, JARDIANCE, Kerendia, LINZESS, Ozempic, REXULTI, Rybelsus, VERQUVO, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error